Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies. | Acta Haematol;144(3): 246-249, 2021. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies.

La Rosée, Felicitas; La Rosée, Paul.

La Rosée F; Medizinische Fakultät, Friedrich-Schiller-Universität, Jena, Germany.
La Rosée P; Medizinische Fakultät, Friedrich-Schiller-Universität, Jena, Germany, Paul.LaRosee@sbk-vs.de.

Acta Haematol ; 144(3): 246-249, 2021.

Article in English | MEDLINE | ID: covidwho-724861

Subject(s)

COVID-19; Hematologic Neoplasms; Hematologic Neoplasms/drug therapy; Humans; Nitriles; Pyrazoles/adverse effects; Pyrimidines; SARS-CoV-2

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematologic Neoplasms / COVID-19 Limits: Humans Language: English Journal: Acta Haematol Year: 2021 Document Type: Article Affiliation country: 000510770

Similar

MEDLINE

LILACS

LIS

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematologic Neoplasms / COVID-19 Limits: Humans Language: English Journal: Acta Haematol Year: 2021 Document Type: Article Affiliation country: 000510770